ArticleIndian journal of pharmacology2026
Comprehensive analysis of etrasimod-related adverse events based on the FDA Adverse Event Reporting System database.
Article in Indian journal of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveEtrasimod, a selective sphingosine-1-phosphate receptor modulator, is a new treatment for ulcerative colitis. This study aims to analyze the real-world distribution of adverse events (AEs) related to Etrasimod using the FDA Adverse Event Reporting System (FAERS) database, identify key AE signals, and provide a comprehensive safety assessment. MATERIALS AND
methodsAE data related to Etrasimod from the FAERS database between Q4 2023 and Q1 2025 were analyzed using frequency-based and Bayesian methods, including reporting odds ratio (ROR), proportional reporting ratio, Bayesian confidence propagation neural network, and Empirical Bayesian Geometric Mean. Data from the FAERS were accessed on July 7, 2025. The authors did not have access to information that could identify individual participants during or after data collection, as FAERS provides only de-identified case reports.
resultsA total of 1284 AE reports were collected, of which 871 were Etrasimod related. Most reports (94.9%) came from the U.S. and primarily involved patients aged 18-65 (66.9%). The most common AEs were related to gastrointestinal disorders and general disorders, with "Drug Ineffective" and "Condition Aggravated" being prominent signals. Eye disorders, including diabetic eye disease and diabetic retinopathy (DR), were identified with high signal strength. New potential AEs such as Type 2 diabetes mellitus and diabetic eye disease were also identified. Severe events such as macular edema and blood cholesterol abnormal, although rare, showed high signal strength.
conclusionEtrasimod's safety risks primarily involve gastrointestinal issues, metabolic disorders, eye diseases, and reactions at the administration site. Most notably and unexpectedly, diabetes-related AEs constituted a prominent new safety signal, including type 2 diabetes, DR, and diabetic eye disease, and should be prioritized in early safety monitoring. Clinicians should monitor high-risk populations closely, especially in the early stages of treatment. Further research is needed to validate these findings and optimize safe use of Etrasimod.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.